CIK 0001815776 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844867570
- Phone
- 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-18 | Versant Venture Capital VI, L.P. 10% owner | Sale | −100,000 | $29.95 | $3.0M | 1,148,789 |
| 2025-06-11 | George Jeffrey P. Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-06-11 | Drapkin Kimberlee C Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-06-11 | Guerard Frederic Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-06-11 | Thunen Shelley B Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-06-11 | MCCOLLUM JAMES W Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-06-11 | Scheiner Zachary Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-06-11 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2025-06-10 | Versant Venture Capital VI, L.P. 10% owner | Sale | −350,000 | $29.00 | $10.2M | 1,248,789 |
| 2025-04-09 | Olsson Shawn Chief Commercial Officer | Option exercise | +1,400 | $2.08 | $3K | 4,733 |
| 2025-04-09 | Olsson Shawn Chief Commercial Officer | Option exercise · Stock Option (right to buy) | −1,400 | 63,241 | ||
| 2025-03-07 | Schimmelpennink Evert B. President, CEO and Secretary | Option exercise | +4,200 | $1.04 | $4K | 49,200 |
| 2025-03-07 | Schimmelpennink Evert B. President, CEO and Secretary | Option exercise · Stock Option (right to buy) | −4,200 | 337,906 | ||
| 2025-01-09 | Olsson Shawn Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +80,100 | 80,100 | ||
| 2025-01-09 | Odrich Marc Chief Medical Officer | Grant or award · Stock Option (right to buy) | +80,100 | 80,100 | ||
| 2025-01-09 | Chevallard Daniel R. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +70,444 | 70,444 | ||
| 2025-01-09 | Schimmelpennink Evert B. President, CEO and Secretary | Grant or award · Stock Option (right to buy) | +279,100 | 279,100 | ||
| 2024-12-16 | Olsson Shawn Chief Commercial Officer | Option exercise | +3,333 | $2.08 | $7K | 3,333 |
| 2024-12-16 | Olsson Shawn Chief Commercial Officer | Option exercise · Stock Option (right to buy) | −3,333 | 64,641 | ||
| 2024-07-22 | Schimmelpennink Evert B. President, CEO and Secretary | Option exercise | +45,000 | $1.04 | $47K | 45,000 |
Page 4 of 11 · 217 trades